Abrupt increased serum creatinine in a hyperferritinemia patient treated with deferoxamine after cord blood transplantation: a case report with literature review

Table 2 Literature review of intravenous deferoxamine associated acute kidney injury

Case	Authors (year)	Age (years)/Gender	Main Diagnosis	Baseline serum creatinine (mg/dL)	Maximal serum creatinine (mg/dL)	AKI onset time	Daily dose (Infusion rate)^a)	Ferritine level (ng/mL)^b)	Outcome
1	Clajus et al (2008) [7]	58/M	Goodpasture’s syndrome ^c)	1.4	2.8	21 days	2g (2.4mg/kg/hr)	1747	Recovery at 2 weeks after cessation
2	Prasannan (2003) [12]	17/M	Sickle cell-beta thalassemia	0.4	2.2	Within hours ^d)	45g (87.5mg/kg/hr)	8000	Recovery after hemodialysis
3	Cianciulli (1992) [13]	19/M	Thalassemia	NA ^e)	6.1	18 hours ^d)	33.7g (39mg/kg/hr)	7000	Recovery after hemodialysis
4	Batey et al (1979) [14]	14/M	Thalassemia	NA	NA ^f)	10 days	3g (NA)	14000	Death
5	Cartei et al (1975) [15]	59/M	Polycythemia rubra vera	1.0	2.0	15 days	3g (NA)^g)	NA	Recovery after dose reduction
6	Cartei et al (1975) [15]	76/M	Sideroblastic Anemia	1.4	3.6	20 days	4g (NA)^g)	NA	Recovery after dose reduction
7	Cartei et al (1975) [15]	67/F	Secondary Hepatopathic Hemochromatosis	0.4	1.5	NA	4g (NA)^g)	NA	Recovery after dose reduction
8	Koren et al (1989) [16]	21/M	Thalassemia	1.1	3	11 days	12.1g (10mg/kg/hr)	5300	Recovery at 5 days after cessation
9	Koren et al (1989) [16]	18/M	Thalassemia	0.8	1.2	10 days	10.3g (10mg/kg/hr)	14000	Recovery at 1 month after cessation
10	Koren et al (1989) [16]	2/F	Ingestion of ferrous fumarate tables	0.4	2.8	1 day	NA (10mg/kg/hr)	284	Recovery at 2 weeks after cessation

In cases 2 and 3, deferoxamine was administrated due to mis-programmed infusion pump. In case 1, Cyclosporine A and furosemide, potential nephrotoxic agents, were concomitantly administrated. In case 4, furosemide, a potential nephrotoxic agent, was concomitantly administrated. In other cases, concomitant agents were not available
Abbreviations: AKI Acute kidney injury, hr Hour, NA Not available
^aDaily dose and infusion rate were shown as the value at the development of AKI
^bThe value at the commencement of deferoxamine therapy
^cThis patient received cadaver kidney transplantation.
^dAKI occurrence time after accidental deferoxamine administration
^eWhile kidney function was controlled, no details were available
^fOliguric renal failure was considered since urine volume was reduced from 1500 mL/24hr to 200mL/24hr
^gFirst 1g was administrated as intramuscular injection, and thereafter as slow infusion

ISSN: 2055-0294